Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and QoL of Aflibercept + FOLFIRI in mCRC
NCT01571284Phase 3Completed
- Sponsor
- Sanofi
- Start
- May 2012
- Primary completion
- Jan 2017
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 23
01
Overview
Phase 3, open-label, single-arm trial of aflibercept in metastatic colorectal cancer (mCRC), sponsored by Sanofi. Primary endpoints: Number of Participants With Treatment-Emergent Adverse Events, Number of Participants With Abnormal Hematological Parameters and 6 more. Started May 2012; status: completed.
02
Drugs
aflibercept
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT01571284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01571284.